Nordea Investment Management
AKBA icon

Nordea Investment Management’s Akebia Therapeutics AKBA Stock Holding History

Nordea Investment Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-752,106
Closed -$1.21M – 866
2025
Q4 		$1.21M Buy
+752,106
New +$1.57M ﹤0.01% 818

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nordea Investment Management's AKBA Position: Q1 2026 in Review

Nordea Investment Management sold out of Akebia Therapeutics (AKBA) in Q1 2026, closing a stake of 752,106 shares — an estimated $1.21M sold.

Nordea Investment Management first reported a position in AKBA in Q4 2025 and held it in 1 quarter. The position peaked at $1.21M in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Nordea Investment Management reported no remaining Akebia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Nordea Investment Management sold 752,106 Akebia Therapeutics shares in Q1 2026, an estimated $1.21M.
  • Nordea Investment Management first reported a position in Akebia Therapeutics in Q4 2025 and held it in 1 quarter.
  • Nordea Investment Management's Akebia Therapeutics position peaked at $1.21M in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Nordea Investment Management's 13F filing for Q1 2026, filed 13 May 2026.